- Trading in AB&B Bio-Tech shares (2627) on Hong Kong Stock Exchange will be suspended from 9:00 a.m. on April 1, 2026.
- Hong Kong Stock Exchange triggered the halt under Listing Rules requirement tied to delayed publication of fiscal 2025 annual results.
- Audit remains incomplete due to ongoing review of certain fund investments plus consultancy payments.
- Board meeting slated for March 31 to consider annual results release was postponed to a date to be announced.
- Trading will remain halted until AB&B Bio-Tech publishes its fiscal 2025 annual results.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260401-12084514), on April 01, 2026, and is solely responsible for the information contained therein.
Comments